Cellectar Biosciences Total Stockholder Equity Over Time
| CLRB Stock | USD 1.54 0.01 0.65% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Cellectar Biosciences Performance and Cellectar Biosciences Correlation. Cellectar |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Stockholder Equity Analysis
Compare Cellectar Biosciences and related stocks such as Diffusion Pharmaceuticals, Monopar Therapeutics, and Pulmatrix Total Stockholder Equity Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MNPR | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 2.8 M | 9.6 M | 6.9 M | 12.6 M | 15.7 M | 18.9 M | 10.1 M | 5.6 M | 10.4 M |
| PULM | (28 K) | (28 K) | 47 K | 14.6 M | 14.6 M | 32.6 M | 8.8 M | 10.1 M | 11.8 M | 11 M | 23.1 M | 47.4 M | 31.1 M | 18 M | 18.9 M |
| TENX | (597.6 K) | (3.7 M) | (346 K) | 82.9 M | 82.9 M | 82.9 M | 17.1 M | 8.9 M | 11.8 M | 3.8 M | 4.6 M | 4.2 M | 1.5 M | 8.1 M | 12.7 M |
| BPTH | (92.3 K) | 2.9 M | 2 M | 4.8 M | 14.9 M | 9.8 M | 8.2 M | 8.1 M | 1.2 M | 21.1 M | 15.1 M | 25.5 M | 14.2 M | 441 K | 418.9 K |
| CAPR | (617) | 830.7 K | (167.3 K) | (534.9 K) | (6.2 M) | (1 M) | (4 M) | 11.2 M | 4.6 M | 6.8 M | 28.2 M | 31.4 M | 11.8 M | 22.6 M | 23.7 M |
| NXTC | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (24.4 M) | (46.9 M) | 321.5 M | 293.7 M | 233.4 M | 167.5 M | 114.4 M | 166.4 M |
| LBPH | 53.1 M | 53.1 M | 53.1 M | 53.1 M | 53.1 M | 53.1 M | 53.1 M | 53.1 M | 53.1 M | 53.1 M | 53.1 M | 103.3 M | 61.5 M | 40.9 M | 51.8 M |
| LUMO | (34.4 M) | 36.8 M | 17.9 M | 58.3 M | 203.8 M | 195.8 M | 129.5 M | 151.6 M | 115.1 M | 78.9 M | 116.6 M | 89 M | 59.6 M | 27.3 M | 25.9 M |
| BOLT | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (15.9 M) | (45.8 M) | (104.9 M) | 250.1 M | 171.5 M | 112.7 M | 67.4 M |
| ALRN | (82 M) | (82 M) | (82 M) | (82 M) | (82 M) | (94.3 M) | (111.8 M) | 47.8 M | 19.6 M | 16 M | 12.2 M | 43.9 M | 18.6 M | 6.9 M | 7.2 M |
| BNTC | 30.6 M | 30.6 M | 30.6 M | 22.5 M | 18.3 M | 14.1 M | 16.5 M | 13.8 M | 16.6 M | 10.2 M | 20 M | 2.9 M | 202 K | 47.2 M | 49.6 M |
Cellectar Biosciences and related stocks such as Diffusion Pharmaceuticals, Monopar Therapeutics, and Pulmatrix Total Stockholder Equity description
The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.My Equities
My Current Equities and Potential Positions
| Cellectar Biosciences | CLRB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.54
Check out Cellectar Biosciences Performance and Cellectar Biosciences Correlation. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Cellectar Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.